IP Library Patent Application 13306336
Patent Application
App. No. 13/306,336

PEG-Urate Oxidase Conjugates and Use Thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/306,336
Abstract

A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.

Claims (20)

1 - 41 . (canceled)

42 . An isolated tetrameric uricase produced by a method comprising

applying a solution of uricase to at least one separation column at a pH of 9 to 10.5; and

recovering from said column one or more fractions that contain isolated tetrameric uricase, wherein said one or more fractions are substantially free of uricase aggregates.

43 . The isolated tetrameric uricase of claim 42 , wherein the uricase is a mammalian uricase or a recombinant form thereof.

44 . The isolated tetrameric uricase of claim 42 , wherein the uricase is a fungal or microbial uricase or a recombinant form thereof.

45 . The isolated tetrameric uricase of claim 44 , wherein the fungal or microbial uricase is isolated from Aspergillus flavus, Arthrobacter globiformis , or Candida utilis , or is a recombinant enzyme having substantially the sequence of one of those uricases.

46 . The isolated tetrameric uricase of claim 42 , wherein the uricase is an invertebrate uricase or a recombinant form thereof.

47 . The isolated tetrameric uricase of claim 46 , wherein the invertebrate uricase is isolated from Drosophila melanogaster or Drosophila pseudoobscura , or is a recombinant enzyme having substantially the sequence of one of those uricases.

48 . The isolated tetrameric uricase of claim 42 , wherein the uricase is a plant uricase or a recombinant form thereof.

49 . The isolated tetrameric uricase of claim 48 , wherein the plant uricase is isolated from root nodules of Glycine max or is a recombinant enzyme having substantially the sequence of that uricase.

50 . The isolated tetrameric uricase of claim 42 , each subunit of the uricase being subsequently covalently linked to an average of 2 to 12 strands of PEG to form a PEG-uricase conjugate, wherein each molecule of PEG has a molecular weight of 5 kDa to 100 kDa.

51 . The isolated tetrameric uricase of claim 50 , wherein the PEG has an average molecular weight of 10 kDa to 60 kDa.

52 . The isolated tetrameric uricase of claim 51 , wherein the PEG has an average molecular weight of 20 kDa to 40 kDa.

53 . The isolated tetrameric unease of claim 50 , wherein the average number of covalently coupled strands of PEG is 2 to 10 strands per uricase subunit.

54 . The isolated tetrameric uricase of claim 53 , wherein the average number of covalently coupled strands of PEG is 3 to 8 strands per uricase subunit.

55 . The isolated tetrameric uricase of claim 54 , wherein the average number of covalently coupled strands of PEG is 4 to 6 strands per uricase subunit.

56 . The isolated tetrameric uricase of claim 50 , wherein the strands of PEG are covalently coupled to uricase via linkages selected from the group consisting of urethane linkages, secondary amine linkages, and amide linkages.

57 . The isolated tetrameric uricase of claim 50 , wherein the PEG is linear.

58 . The isolated tetrameric uricase of claim 50 , wherein the PEG is branched.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062294/0205 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0163 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0073 →
SECURITY INTEREST Recorded Aug 11, 2015
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 036300/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2015
From: MOUNTAIN VIEW PHARMACEUTICALS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036240/0827 →
SECURITY INTEREST Recorded Jul 21, 2015
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 036142/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: WILLIAMS, L. DAVID; SAIFER, MARK G.P.; SHERMAN, MERRY R.
To: MOUNTAIN VIEW PHARMACEUTICALS, INC.
Reel/Frame 032903/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: HERSHFIELD, MICHAEL S.; KELLY, SUSAN J.
To: DUKE UNIVERSITY
Reel/Frame 032903/0941 →